Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.

Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis

Open access

Abstract

Background: The anti-inflammatory effect could be one of the mechanisms by which semaglutide reduces cardiovascular risk in patients with type 2 diabetes mellitus (T2DM) and/or obesity. Determining the anti-inflammatory effect of semaglutide was the objective of this systematic review and meta-analysis. Methods: This meta-analysis was performed according to the PRISMA guidelines. A literature search was performed to detect randomised clinical trials that have quantified the effect of semaglutide on C-reactive protein (CRP) levels compared to placebo or a control group (other glucose-lowering drugs). The primary outcome was CRP index (final CRP/basal CRP). A random-effects model was used. Results: Thirteen randomised clinical trials were considered eligible ( n = 26,131). Overall, semaglutide therapy was associated with lower CRP index values compared to the placebo group (SMD −0.56; 95% CI −0.69 to −0.43, I 2 92%) or the control group (SMD −0.45; 95% CI −0.68 to −0.23, I 2 82%).Such an association was similarly observed when different treatment regimens (subcutaneous vs. oral) or different populations (patients with or without T2DM) were analysed. The sensitivity analysis showed that the results were robust. Conclusion: The present meta-analysis demonstrated that the use of semaglutide was associated with a reduction in inflammation irrespective of the population evaluated or the treatment regimen used. These findings would explain one of the mechanisms by which semaglutide reduces cardiovascular events. Systematic Review Registration: PROSPERO [CRD42024500551].

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fcvm.2024.1379189

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow diagram of the study selection process.
Figure 1 Flow diagram of the study selection process.CC BY · PubMed Central
Figure 2 Summary and evaluation of individual bias of included studies.
Figure 2 Summary and evaluation of individual bias of included studies.CC BY · PubMed Central
Figure 3 Effect of semaglutide therapy on CRP index. Random-effects model, standardised mean differences (SMD), 95% confidence intervals (CI) and statistical I2. Top: semaglutide vs. placebo trial group. Bottom: group of studies with semaglitide versus other drugs. PIONEER-1 a, b and c: semaglutide 3, 7 and 14 mg orally, respectively. STEP-2 a and b: semaglutide 2.4 mg and 1 mg subcutaneous, respectively. STEP-6 a and b: semaglutide 2.4 mg and 1.7 mg subcutaneously, respectively. STEP-8b: semaglutide 2.4 mg arm vs placebo.
Figure 3 Effect of semaglutide therapy on CRP index. Random-effects model, standardised mean differences (SMD), 95% confidence intervals (CI) and statistical I2. Top: semaglutide vs. placebo trial group. Bottom: group of studies with semaglitide versus other drugs. PIONEER-1 a, b and c: semaglutide 3, 7 and 14 mg orally, respectively. STEP-2 a and b: semaglutide 2.4 mg and 1 mg subcutaneous, respectively. STEP-6 a and b: semaglutide 2.4 mg and 1.7 mg subcutaneously, respectively. STEP-8b: semaglutide 2.4 mg arm vs placebo.CC BY · PubMed Central
Figure 4 Effect of semaglutide therapy on CRP rate stratified by groups of patients with or without type 2 diabetes mellitus (T2DM). Analysis performed only with trials vs. placebo. Random-effects model, standardised mean differences (SMD), 95% confidence intervals (CI) and statistical I2. PIONEER-1 a, b and c: semaglutide 3, 7 and 14 mg orally, respectively. STEP-2 a and b: semaglutide 2.4 mg and 1 mg subcutaneous, respectively. STEP-6 a and b: semaglutide 2.4 mg and 1.7 mg subcutaneously, respectively. STEP-8b: semaglutide 2.4 mg arm vs placebo.
Figure 4 Effect of semaglutide therapy on CRP rate stratified by groups of patients with or without type 2 diabetes mellitus (T2DM). Analysis performed only with trials vs. placebo. Random-effects model, standardised mean differences (SMD), 95% confidence intervals (CI) and statistical I2. PIONEER-1 a, b and c: semaglutide 3, 7 and 14 mg orally, respectively. STEP-2 a and b: semaglutide 2.4 mg and 1 mg subcutaneous, respectively. STEP-6 a and b: semaglutide 2.4 mg and 1.7 mg subcutaneously, respectively. STEP-8b: semaglutide 2.4 mg arm vs placebo.CC BY · PubMed Central
Figure 5 The effect of semaglutide therapy on the stratified CRP rate by the way semaglutide was administered in diabetic (A) and non-diabetic population (B). Analysis performed only with trials vs. placebo. Random-effects model, standardised mean differences (SMD), 95% confidence intervals (CI) and statistical I2. PIONEER-1 a, b and c: semaglutide 3, 7 and 14 mg orally, respectively. STEP-2 a and b: semaglutide 2.4 mg and 1 mg subcutaneous, respectively. STEP-6 a and b: semaglutide 2.4 mg and 1.7 mg subcutaneously, respectively. STEP-8b: semaglutide 2.4 mg arm vs. placebo.
Figure 5 The effect of semaglutide therapy on the stratified CRP rate by the way semaglutide was administered in diabetic (A) and non-diabetic population (B). Analysis performed only with trials vs. placebo. Random-effects model, standardised mean differences (SMD), 95% confidence intervals (CI) and statistical I2. PIONEER-1 a, b and c: semaglutide 3, 7 and 14 mg orally, respectively. STEP-2 a and b: semaglutide 2.4 mg and 1 mg subcutaneous, respectively. STEP-6 a and b: semaglutide 2.4 mg and 1.7 mg subcutaneously, respectively. STEP-8b: semaglutide 2.4 mg arm vs. placebo.CC BY · PubMed Central
Figure 6 Sensitivity analysis. (A) Semaglutide versus placebo trial group. (B) Group of studies with semaglitide versus other drugs. PIONEER-1 a, b and c: semaglutide 3, 7 and 14 mg orally, respectively. STEP-2 a and b: semaglutide 2.4 mg and 1 mg subcutaneous, respectively. STEP-6 a and b: semaglutide 2.4 mg and 1.7 mg subcutaneously, respectively. STEP-8b: semaglutide 2.4 mg arm vs. placebo.
Figure 6 Sensitivity analysis. (A) Semaglutide versus placebo trial group. (B) Group of studies with semaglitide versus other drugs. PIONEER-1 a, b and c: semaglutide 3, 7 and 14 mg orally, respectively. STEP-2 a and b: semaglutide 2.4 mg and 1 mg subcutaneous, respectively. STEP-6 a and b: semaglutide 2.4 mg and 1.7 mg subcutaneously, respectively. STEP-8b: semaglutide 2.4 mg arm vs. placebo.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 66 references

Research works printed but not linked: 1

  1. White-Flowers, 2010, Obesity as an inflammatory process, Bol Med Hosp Infant Mex, 67, 88

Cited by

See all 58

Metadata

Authors
Masson, W., Lobo, M., Nogueira, J. P., Rodriguez-Granillo, A. M., Barbagelata, L. E., & Siniawski, D.
Affiliations
  • Hospital Italiano de Buenos Aires (AR)
  • Universidad Internacional de las Américas (CR)
  • Sanatorio Otamendi y Miroli (AR)
Corresponding author
Masson, Walter
Venue
Frontiers in Cardiovascular Medicine
Published
2024-07-05
Volume
11
Pages
1379189-1379189
ISSN
2297-055X (ISSN-L)
OpenAlex
W4400369011
Cited by
57
References
66
Citations by year
2026: 29 · 2025: 27 · 2024: 1
FWCI
3.35
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Cardiovascular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
semaglutide, anti-inflammatory activity, C-reactive protein, type 2 diabetes, obesity, cardiovascular risk reduction, GLP-1 receptor agonists, inflammation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis. https://app.cochat.ai/papers/10.3389/fcvm.2024.1379189
The paper
Masson, W., Lobo, M., Nogueira, J. P., Rodriguez-Granillo, A. M., Barbagelata, L. E., & Siniawski, D. (2024). Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis. Frontiers in Cardiovascular Medicine. https://doi.org/10.3389/fcvm.2024.1379189

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.